We are live on ! Find out more
SPRY icon

ARS Pharmaceuticals
SPRY

76 hedge funds and large institutions have $864M invested in ARS Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 10

32% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 19

12% more funds holding

Funds holding: 68 → 76 (+8)

0.58% more ownership

Funds ownership: 79.6% → 80.18% (+0.58%)

28% less capital invested

Capital invested by funds: $1.21B → $864M (-$341M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
76
Holders Change
+8
Holders Change %
+11.76%
% of All Funds
1.32%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
18
Increased
25
Reduced
19
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
WA
Wasatch Advisors
Utah
+$12.2M
2
NCM
Nantahala Capital Management
Connecticut
+$8.79M
3
CS
Candriam SCA
Luxembourg
+$6.3M
4
WP
Woodline Partners
California
+$5.48M
5
ECM
Endurant Capital Management
California
+$4.46M

Top Sellers

1
BlackRock
BlackRock
New York
-$10.9M
2
CAM
Cormorant Asset Management
Massachusetts
-$8.37M
3
LGM
Logos Global Management
California
-$5.45M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.41M
5
VA
VR Adviser
New York
-$3.71M
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$270M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$145M -$4.41M -137,591 -3%
EC
3
EcoR1 Capital
California
$80.9M +$2.71M +84,401 +3%
RCM
4
RA Capital Management
Massachusetts
$53.8M – – –
BC
5
Boxer Capital
California
$51.8M – – –
NCM
6
Nantahala Capital Management
Connecticut
$39.1M +$8.79M +274,024 +28%
Vanguard Group
7
Vanguard Group
Pennsylvania
$30.8M -$2.88M -89,942 -8%
BlackRock
8
BlackRock
New York
$27.2M -$10.9M -339,903 -28%
WA
9
Wasatch Advisors
Utah
$19.9M +$12.2M +379,467 +142%
Ameriprise
10
Ameriprise
Minnesota
$13.8M +$731K +22,797 +5%
WP
11
Woodline Partners
California
$11.7M +$5.48M +170,948 +83%
EAM
12
Eventide Asset Management
Massachusetts
$11.5M – – –
CAM
13
Cormorant Asset Management
Massachusetts
$7.39M -$8.37M -260,901 -52%
BBA
14
Baker Bros. Advisors
New York
$7.36M – – –
State Street
15
State Street
Massachusetts
$6.93M +$1.03M +32,155 +17%
Franklin Resources
16
Franklin Resources
California
$6.93M +$776K +24,200 +12%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$6.82M +$66.3K +2,067 +0.9%
D.E. Shaw & Co
18
D.E. Shaw & Co
New York
$6.49M +$151K +4,714 +2%
CS
19
Candriam SCA
Luxembourg
$6.07M +$6.3M +196,544 +1,511,877%
Point72 Asset Management
20
Point72 Asset Management
Connecticut
$5.96M -$3.03M -94,604 -33%
PHS
21
PFM Health Sciences
California
$5.82M – – –
SFM
22
Sphera Funds Management
Israel
$5.37M +$195K +6,092 +4%
Schroder Investment Management Group
23
Schroder Investment Management Group
United Kingdom
$5.06M +$1.9M +59,258 +57%
ECM
24
Endurant Capital Management
California
$4.3M +$4.46M +139,124 New
ABG
25
Ally Bridge Group
New York
$3.97M – – –
1
2 3 4

SPRY Hedge Fund Activity: Q2 2021 in Review

76 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q2 2021, worth a combined $864M — down 28% from $1.21B a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new SPRY positions and 10 closed out — a net gain of 8 holders — while 25 added to existing stakes and 19 trimmed.

The largest buyer was Wasatch Advisors, adding an estimated $12.2M. The largest seller was BlackRock, cutting an estimated $10.9M.

  • 76 institutional investors held ARS Pharmaceuticals (SPRY) as of Q2 2021, up from 68 in Q1 2021.
  • Funds reported $864M of ARS Pharmaceuticals stock for Q2 2021, down 28% quarter-over-quarter.
  • 18 funds opened new ARS Pharmaceuticals positions in Q2 2021 and 10 closed out, a net change of +8 holders.
  • The largest ARS Pharmaceuticals buyer in Q2 2021 was Wasatch Advisors, an estimated $12.2M added.
  • The largest ARS Pharmaceuticals seller in Q2 2021 was BlackRock, an estimated $10.9M sold.

Based on aggregated 13F filings for Q2 2021.